Who are Xelstrym's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Strattera, Propadrine, Edronax, Rilutek, Fenmetrazina, Sanorex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexamfetamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Xelstrym — Competitive Intelligence Brief

Xelstrym (dexamfetamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central Nervous System Stimulant [EPC]. Area: Nephrology.

marketed Central Nervous System Stimulant [EPC] Sodium-dependent noradrenaline transporter Nephrology Live · refreshed every 30 min

Target snapshot

Xelstrym (dexamfetamine) — UCB. Xelstrym works by blocking the reuptake of noradrenaline, allowing it to stay in the brain for longer and increasing alertness and focus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xelstrym TARGET	dexamfetamine	UCB	marketed	Central Nervous System Stimulant [EPC]	Sodium-dependent noradrenaline transporter	1955-01-01
Strattera	ATOMOXETINE	Eli Lilly	marketed	Norepinephrine Reuptake Inhibitor	Sodium-dependent noradrenaline transporter	2002-01-01
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	marketed	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Edronax	REBOXETINE		marketed	reboxetine	Sodium-dependent noradrenaline transporter	1997-01-01
Rilutek	RILUZOLE	Covis	marketed	Benzothiazole [EPC]	Sodium-dependent noradrenaline transporter	1995-01-01
Fenmetrazina	PHENMETRAZINE	Boehringer Ingelheim	marketed	phenmetrazine	Sodium-dependent noradrenaline transporter	1982-01-01
Sanorex	MAZINDOL		marketed	mazindol	Sodium-dependent noradrenaline transporter	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-03-12 — Rilutek · 8765150 · Formulation · US
2029-08-24 — Xelstrym · 8846100 · US
2033-10-24 — Xelstrym · 9456993 · US
2033-10-24 — Xelstrym · 9474722 · US
2042-01-06 — Xelstrym · 11559501 · US

Sponsor landscape (Central Nervous System Stimulant [EPC] class)

· 5 drugs in this class
Caraco · 1 drug in this class
Hikma · 1 drug in this class
Impax Labs · 1 drug in this class
Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class
UCB · 1 drug in this class
University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xelstrym — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamfetamine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab